What is Takeda Pharmaceutical's stock price target for 2024?

0 brokers have issued twelve-month target prices for Takeda Pharmaceutical's stock. Their TAK share price targets range from $14.00 to $14.00. On average, they predict the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View analysts price targets for TAK or view top-rated stocks among Wall Street analysts .

How have TAK shares performed in 2024?

Takeda Pharmaceutical's stock was trading at $14.27 at the start of the year. Since then, TAK stock has decreased by 8.1% and is now trading at $13.11. View the best growth stocks for 2024 here .

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 5,970,000 shares, a decrease of 26.5% from the March 31st total of 8,120,000 shares. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is presently 3.2 days. Currently, 0.2% of the company's stock are short sold. View Takeda Pharmaceutical's Short Interest .

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TAK earnings forecast .

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings data on Thursday, February, 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm earned $7.52 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.57% and a net margin of 6.90%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.52 per share and currently has a dividend yield of 3.90%. The dividend payout ratio is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, TAK will have a dividend payout ratio of 41.60% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?

ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH) , B.A.D. Etf (BAD) and ActivePassive International Equity ETF (APIE) . Amplify Treatments, Testing and Advancements ETF (GERM) .

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of 3.030-3.030 for the period. The company issued revenue guidance of $26.9 billion-$26.9 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO) , Johnson & Johnson (JNJ) , Alibaba Group (BABA) , Pfizer (PFE) , Verizon Communications (VZ) , AbbVie (ABBV) , CVS Health (CVS) , Gilead Sciences (GILD) , AT&T (T) and Abbott Laboratories (ABT) .

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplicity Wealth LLC (0.01%), Legacy Wealth Asset Management LLC (0.00%), Wealth Enhancement Advisory Services LLC (0.00%), Naviter Wealth LLC (0.00%), First Trust Direct Indexing L.P. (0.00%) and NBC Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix. Read More

NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Free TAK Stock Alerts

$13.06

-0.17 (-1.28%)

(As of 03:58 PM ET)

Compare

Today's Range: $13.05
▼
$13.19
50-Day Range: $13.16
▼
$14.86
52-Week Range: $13.05
▼
$17.11

Volume: 1.43 million shs
Average Volume: 1.82 million shs
Market Capitalization: $41.33 billion

P/E Ratio: 19.79
Dividend Yield: 3.98%
Price Target: $14.00

Get Takeda Pharmaceutical alerts:

Takeda Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 6.8% Upside
$14.00 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.27
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -16.67%
From $1.50 to $1.25 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.66 out of 5 stars

Medical Sector

879th out of 907 stocks

Pharmaceutical Preparations Industry

412th out of 422 stocks

0.0

Analyst's Opinion

Amount of Analyst Coverage
Takeda Pharmaceutical has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently decreased by 26.48%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Leadership
Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.90%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 41.60% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

1.8

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.
MarketBeat Follows
Only 1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Takeda Pharmaceutical are expected to decrease by -16.67% in the coming year, from $1.50 to $1.25 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 19.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.00.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 19.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 194.35.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

About Takeda Pharmaceutical Stock (NYSE:TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TAK Stock News Headlines

April 24, 2024 | msn.com

Japan’s SMBC joins JV to support drug discovery start-ups

April 23, 2024 | finance.yahoo.com

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

April 25, 2024 | Stansberry Research (Ad)

Mysterious Gold Leverage Just Announced

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

April 22, 2024 | prnewswire.com

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

April 19, 2024 | benzinga.com

Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals

April 18, 2024 | finance.yahoo.com

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

April 18, 2024 | businesswire.com

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

April 16, 2024 | finance.yahoo.com

Takeda Pharmaceutical Company Limited (4502.T)

April 25, 2024 | Stansberry Research (Ad)

Mysterious Gold Leverage Just Announced

April 8, 2024 | businesswire.com

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

April 2, 2024 | businesswire.com

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

April 1, 2024 | finance.yahoo.com

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

March 28, 2024 | usnews.com

Puerto Rico Declares Dengue Epidemic as Cases Climb

March 27, 2024 | prnewswire.com

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

March 26, 2024 | businesswire.com

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

March 26, 2024 | markets.businessinsider.com

Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan

March 26, 2024 | finance.yahoo.com

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

March 21, 2024 | finance.yahoo.com

The Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growth

March 19, 2024 | markets.businessinsider.com

Takeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALL

March 19, 2024 | businesswire.com

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

March 18, 2024 | businesswire.com

Advanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]

March 15, 2024 | finanznachrichten.de

Takeda Pharmaceuticals: Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa

March 13, 2024 | finance.yahoo.com

Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

March 13, 2024 | finance.yahoo.com

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

March 5, 2024 | seekingalpha.com

Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds

March 5, 2024 | bizjournals.com

Five things: Takeda's big lease, more biotech cuts, Ted Williams' jersey and a basketball bandwagon

March 4, 2024 | msn.com

Takeda staying in Kendall Square

See More Headlines

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/01/2024
Today: 4/25/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 49,095
Year Founded: 1781

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $14.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +5.8%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.66
Trailing P/E Ratio: 20.05
Forward P/E Ratio: 8.82
P/E Growth: 3.79
Net Income: $2.35 billion
Net Margins: 6.90%
Pretax Margin: 3.72%
Return on Equity: 12.57%
Return on Assets: 5.89%

Debt

Debt-to-Equity Ratio: 0.64
Current Ratio: 1.06
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $29.81 billion
Price / Sales: 1.40
Cash Flow: $3.55 per share
Price / Cash Flow: 3.73
Book Value: $14.86 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 3,164,820,000
Free Float: 3,163,552,000
Market Cap: $41.87 billion
Optionable: Optionable
Beta: 0.53

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Christophe Weber (Age 58)
President, CEO & Representative Director
Comp: $3.74M
Dr. Andrew S. Plump (Age 59)
President of Research & Development and Representative Director
Comp: $2.67M
Dr. Seigo Izumo
Chair of Management Board
Mr. Milano Furuta (Age 46)
Chief Financial Officer
Mr. Haruhiko Hirate (Age 67)
Member of Management Board
Mr. Salvatore Alesci M.D. (Age 49)
Ph.D., Member of Management Board and Head of R&D Global Science & Biomedical Policy
Norimasa Takeda
Chief Accounting Officer & Corporate Controller
Mr. Iwaaki Taniguchi
Senior Vice President of Corporate Finance & Controlling Department
Mr. Gabriele Ricci (Age 46)
Chief Data & Technology Officer
Mr. Christopher David O'Reilly
Global Head of Investor Relations & Global Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

Takeda Pharmaceutical has a diverse portfolio of pharmaceutical products in areas such as gastroenterology, rare diseases, oncology, and neuroscience, providing revenue stability and growth potential.
The company has been actively engaging in collaborations and licensing agreements with various biotech and pharmaceutical companies, enhancing its research and development capabilities and potentially leading to innovative product launches.
Recent increase in institutional investments in Takeda Pharmaceutical, indicating confidence from major investors in the company's growth prospects.
Takeda Pharmaceutical's stock price has shown resilience and stability, with a market cap of $42.68 billion, indicating a strong position in the market.
The company's global presence and established history since 1781 provide a solid foundation for long-term growth and sustainability in the pharmaceutical industry.

Cons

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

Takeda Pharmaceutical's PEG ratio of 3.83 may indicate that the stock is overvalued compared to its earnings growth potential, potentially leading to limited upside for investors.
The company's debt-to-equity ratio of 0.64 suggests a moderate level of debt, which could pose risks in case of economic downturns or financial challenges.
Takeda Pharmaceutical's current ratio of 1.06 may indicate a lower liquidity position, which could impact the company's ability to meet short-term financial obligations.
The beta of 0.53 for Takeda Pharmaceutical implies lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking higher returns.
Despite collaborations and licensing agreements, the competitive nature of the pharmaceutical industry poses challenges in maintaining market share and profitability, which could affect investor returns.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

TAK Stock Analysis - Frequently Asked Questions

What is Takeda Pharmaceutical's stock price target for 2024?: 0 brokers have issued twelve-month target prices for Takeda Pharmaceutical's stock. Their TAK share price targets range from $14.00 to $14.00. On average, they predict the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2024?: Takeda Pharmaceutical's stock was trading at $14.27 at the start of the year. Since then, TAK stock has decreased by 8.1% and is now trading at $13.11.
View the best growth stocks for 2024 here.
Are investors shorting Takeda Pharmaceutical?: Takeda Pharmaceutical saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 5,970,000 shares, a decrease of 26.5% from the March 31st total of 8,120,000 shares. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is presently 3.2 days. Currently, 0.2% of the company's stock are short sold.
View Takeda Pharmaceutical's Short Interest.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TAK earnings forecast.
How were Takeda Pharmaceutical's earnings last quarter?: Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings data on Thursday, February, 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm earned $7.52 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.57% and a net margin of 6.90%.
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.52 per share and currently has a dividend yield of 3.90%. The dividend payout ratio is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, TAK will have a dividend payout ratio of 41.60% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?: ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), B.A.D. Etf (BAD) and ActivePassive International Equity ETF (APIE).Amplify Treatments, Testing and Advancements ETF (GERM).
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of 3.030-3.030 for the period. The company issued revenue guidance of $26.9 billion-$26.9 billion.
What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).
Who are Takeda Pharmaceutical's major shareholders?: Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplicity Wealth LLC (0.01%), Legacy Wealth Asset Management LLC (0.00%), Wealth Enhancement Advisory Services LLC (0.00%), Naviter Wealth LLC (0.00%), First Trust Direct Indexing L.P. (0.00%) and NBC Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More

This page (NYSE:TAK) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial